Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
Nanox Imaging Ltd (NASDAQ: NNOX) is transforming medical diagnostics through its digital X-ray systems and AI-powered imaging analytics. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements, regulatory milestones, and market developments.
Access real-time information on product launches, financial results, clinical partnerships, and technology patents. Our curated collection includes official press releases about the Nanox.ARC imaging system updates, Nanox.AI algorithm enhancements, and global deployment of cloud-based diagnostic solutions.
Stay informed about developments in medical imaging innovation while tracking the company's progress in making preventive care more accessible through cost-effective solutions. Bookmark this page for verified updates about FDA clearances, research collaborations, and operational expansions that shape the future of diagnostic technology.
Zebra Medical Vision has announced its eighth FDA 510(k) clearance for the HealthCCSng solution, designed to quantify coronary artery calcium (CAC) in existing non-gated CT scans to identify patients at risk for cardiovascular disease. This innovation aims to facilitate early diagnosis and treatment, thereby reducing healthcare costs. Zebra-Med's collaboration with Nanox is expected to enhance its AI capabilities and reach, supporting population health management and preventative care. The company emphasizes its commitment to improving healthcare outcomes through advanced imaging technologies.
Nano-X Imaging Ltd (Nasdaq: NNOX) announces an AI Vision event on October 27, 2021, at 8:30am ET. Hosted by Chairman and CEO Ran Poliakine and Director Erez Meltzer, the event will showcase the integration of AI technologies with Nano-X's imaging solutions, Nanox.ARC and Nanox.SOURCE. This initiative aims to enhance medical imaging systems' affordability and accessibility. The company seeks collaborations with healthcare organizations to provide early detection services. For more details, visit www.nanox.vision.
Nanox, a pioneering medical imaging technology company, announced that its CEO, Ran Poliakine, and Executive Chairman, Erez Meltzer, will present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021, at 9:20 AM ET. A live webcast will be available through the company's website, with a replay accessible afterward. Nanox is focused on revolutionizing medical imaging by developing an affordable digital X-ray source aimed at collaboration with leading healthcare organizations to improve early detection imaging services.
Nanox to Host Business Update Webcast
On August 12, 2021, Nanox, a medical imaging technology company traded under NASDAQ: NNOX, announced a Business Update Video Presentation scheduled for August 16, 2021, at 8:30 am ET. CEO Ran Poliakine and senior leadership will discuss company advancements. Interested participants can register through the provided link. Nanox aims to reduce medical imaging costs with its innovative digital X-ray technology and seeks collaborations for affordable imaging services.
Nanox has announced a merger agreement with Zebra Medical Vision for $100 million upfront and $100 million in milestone payments. Additionally, it has entered a binding letter of intent to acquire USARAD Holdings Inc. for $30 million, comprising $21 million in shares and $9 million cash. These acquisitions aim to create a globally connected radiology solution and enhance population health management. Notably, Zebra Medical brings advanced AI technology and established relationships with healthcare providers worldwide.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced a merger agreement to acquire Zebra Medical Vision for $100 million upfront and additional milestone payments. The company also signed a letter of intent to acquire USARAD for $30 million. These acquisitions aim to enhance their global radiology services and population health management. As of June 30, 2021, NANO-X reported a net loss of $13.6 million, with cash reserves of $193.4 million. Management transitions include Erez Meltzer becoming CEO in January 2022, with Ran Poliakine continuing as Executive Chairman.
NANO-X IMAGING LTD (NASDAQ: NNOX) will announce its Q2 2021 financial results on August 10, 2021, prior to market open. A conference call and webcast will be held at 8:30 AM ET on the same day. The company aims to revolutionize medical imaging with its commercial-grade digital X-ray technology, designed to lower costs and improve accessibility. Nanox plans to partner with leading healthcare organizations to enhance early detection services. Further details can be found on their website.
NANO-X IMAGING LTD (NNOX) has entered the West African market by signing an exclusive distribution agreement with EiLEENO Pharma to deploy 1,000 Nanox Systems in Nigeria, pending regulatory approval. This collaboration aims to enhance medical imaging availability and improve healthcare standards in the country. The agreement has a four-year term with annual service fees from EiLEENO Pharma. The Nanox System includes the innovative Nanox.ARC imaging device and Nanox.CLOUD software, which promises to facilitate accessible healthcare services across roughly 4,400 health facilities in Nigeria.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that CEO Ran Poliakine will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00 AM ET. The live presentation can be accessed through a webcast, and a replay will be available after the event. Nanox focuses on developing a digital X-ray source aimed at reducing medical imaging costs and providing affordable early detection services. Interested parties can find more details on the company's investor relations website.
NANOX IMAGING LTD (NASDAQ: NNOX) announced a significant milestone by submitting a 510(k) premarket notification to the FDA for its multi-source Nanox.ARC 3-D digital tomosynthesis system. This system aims to address the global need for accessible and cost-effective medical imaging. The submission is a crucial step in the U.S. regulatory process following the FDA clearance of its single source Nanox Cart X-Ray System in April 2021. NANOX plans to develop future versions of the Nanox.ARC to fulfill existing service contracts and collaborations.
